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6XPPDU\ 28 
Background Carbapenems are frequently the last line of defence in serious 29 
infections due to multi-drug-resistant Gram-negative bacteria but their use is 30 
threatened by the growing prevalence of carbapenemase-producing pathogens. 31 
Ceftazidime-avibactam represents a potential new agent for use in such infections. 32 
Methods REPRISE (NCT01644643) was a prospective, pathogen-directed, 33 
international, randomised, open-label, phase 3 trial comparing the efficacy and 34 
safety of treatment with ceftazidime-avibactam 2000±500 mg versus best available 35 
therapy in adults with complicated urinary tract infections (cUTI) or complicated intra-36 
abdominal infections (cIAI) due to ceftazidime-resistant Enterobacteriaceae or 37 
Pseudomonas aeruginosa. The primary endpoint was assessment of clinical 38 
response at test-of-cure (TOC) visit 7±10 days after last infusion of study therapy in 39 
the microbiologically modified intent-to-treat (mMITT) population. 40 
Findings Between January 2013 and August 2014, 333 patients were enrolled and 41 
randomised in 16 countries worldwide, of whom 302 (90·7%) were included in the 42 
mMITT population (281 cUTI, 21 cIAI). Most (97%) patients on best available therapy 43 
received a carbapenem, usually as monotherapy. The overall clinical cure rate at 44 
TOC in the mMITT population was similar with ceftazidime-avibactam (140/154 45 
[90·9%; 95% confidence interval (CI), 85·6, 94·7]) and best available therapy 46 
(135/148 [91·2%; 95% CI, 85·9, 95·0]). The per-patient favourable microbiological 47 
response rate at TOC in cUTI patients was higher with ceftazidime-avibactam 48 
(118/144 [81·9%; 95% CI, 75·1, 87·6]) than with best available therapy (88/137 49 
[64·2%; 95% CI, 56·0, 71·9]). No new safety concerns were identified for 50 
ceftazidime-avibactam. 51 
4 
Interpretation These results provide evidence of the efficacy of ceftazidime-52 
avibactam as a potential alternative to carbapenems in patients with ceftazidime 53 
resistant Enterobacteriaceae and P. aeruginosa. 54 
 55 
Funding: The REPRISE study was supported by AstraZeneca. 56 
Keywords: Ceftazidime-avibactam; ceftazidime-resistant, carbapenem-resistant, 57 
MDR Gram-negative, pathogen-directed study, complicated urinary tract infections, 58 
complicated intra-abdominal infections  59 
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,QWURGXFWLRQ 60 
The prevalence of multi-drug resistant (MDR) Gram-negative pathogens, including 61 
extended-spectrum ȕ-lactamase (ESBL)-producing and carbapenemase-producing 62 
Enterobacteriaceae and Pseudomonas aeruginosa, is increasing worldwide.1±3 63 
Contributing factors are the extensive use of antibiotics, both in humans and 64 
animals, poor infection control, and the greatly increased global mobility of people, 65 
allowing the rapid spread of MDR pathogens.1,4,5 As the prevalence of ESBL-66 
producing pathogens has increased, so has the use of carbapenem antibiotics ± 67 
frequently the last line of defence against MDR Gram-negative bacteria but now 68 
threatened by the growing prevalence of carbapenemase-producing pathogens.6 69 
There is therefore an urgent need to find alternative treatment options and 70 
carbapenem-sparing regimens for patients with serious infections caused by MDR 71 
Gram-negative pathogens. 72 
Ceftazidime-avibactam may represent an important new option for such 73 
cases, comprising ceftazidime, a widely used expanded-spectrum anti-pseudomonal 74 
cephalosporin, and avibactam, a novel non-ȕ-ODFWDPȕ-lactamase inhibitor.7,8 75 
Avibactam has a broader spectrum of activity than currently available ȕ-lactamase 76 
inhibitors, and has been shown in vitro to restore the activity of ceftazidime against 77 
most MDR Enterobacteriaceae and P. aeruginosa by inhibiting a wide variety of 78 
ȕ-lactamases, including class A (including ESBLs, Klebsiella pneumoniae 79 
carbapenemases [KPC]), class C (AmpC), and some class D enzymes 80 
(e.g. OXA-48).9 81 
Two phase 3 studies of ceftazidime-avibactam in patients with complicated 82 
intra-abdominal infection (cIAI) (RECLAIM 1 and 2 [NCT01499290 and 83 
6 
NCT01500239]) have recently been reported,10 and other phase 3 trials are ongoing, 84 
including patients with complicated urinary tract infections (cUTI) (RECAPTURE 1 85 
and 2 [NCT01595438 and NCT01599806]), cIAI (RECLAIM 3 [NCT01726023]) and 86 
nosocomial pneumonia (REPROVE [NCT01808092]). However, based on data from 87 
phase 2 trials,7,8 the United States Food and Drug Administration recently approved 88 
ceftazidime-avibactam for use in the treatment of adults with cIAI, in combination 89 
with metronidazole, and cUTI, including kidney infections (pyelonephritis), who have 90 
limited or no alternative treatment options.11  91 
The phase 3 studies listed above enrolled patients with or without drug-92 
resistant pathogens. Thus, although they can provide valuable information on safety, 93 
tolerability, and efficacy, they may not provide extensive information on efficacy 94 
against resistant pathogens. Given the need for new therapies to treat patients with 95 
drug-resistant infections, pathogen-directed studies have been recommended.12 The 96 
international, randomised, phase 3 study (REPRISE; NCT01644643) reported here 97 
is the first MDR Gram-negative pathogen-directed study for ceftazidime-avibactam, 98 
focussing specifically on the efficacy, safety, and tolerability in patients with cUTI or 99 
cIAI due to ceftazidime-resistant Gram-negative pathogens.  100 
 101 
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Study design 103 
REPRISE was a prospective, international, randomised, open-label, phase 3 trial. As 104 
summarised in figure S1 (appendix), eligible patients were randomised in a 1:1 ratio 105 
to receive 5±21 days of treatment with either ceftazidime-avibactam 2000±500 mg, 106 
administered together as a 2-h intravenous (IV) infusion every 8 h, or best available 107 
therapy. Randomisation codes were computer-generated using the AstraZeneca 108 
Global Randomization Scheme. Patients were stratified by entry diagnosis (cUTI and 109 
cIAI) and by region: (1) North America and Western Europe; (2) Eastern Europe; and 110 
(3) Rest of World. Best available therapy was determined by the investigator based 111 
on standard of care and local label recommendations, and was documented prior to 112 
randomisation. Preferred best available therapy options for cUTI and cIAI were 113 
meropenem, imipenem, doripenem, colistin, and (for cIAI) tigecycline, but any 114 
therapy, including combination treatment, was permitted. Patients with cUTI had two 115 
follow-up visits, at 21±25 days (FU1) and 28±32 days (FU2) from randomisation. 116 
Patients with cIAI had only one follow-up visit at 28±35 days from randomisation 117 
(FU1) (appendix). 118 
As ceftazidime and avibactam are predominantly cleared renally,13 119 
ceftazidime-avibactam dose modifications were made for patients with moderate to 120 
severe renal impairment (estimated creatinine clearance 6±50 mL/min) (appendix). 121 
Patients with cIAI who were randomised to ceftazidime-avibactam also received IV 122 
metronidazole 500 mg, administered as a 60-min infusion every 8 h, immediately 123 
after the ceftazidime-avibactam infusion, for anaerobe coverage. 124 
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The study was performed in accordance with the ethical principles that have 125 
their origin in the Declaration of Helsinki, and are consistent with International 126 
Conference on Harmonisation harmonised tripartite guideline E6(R1) Good Clinical 127 
Practice, applicable regulatory requirements, and the 6SRQVRU¶V policy on Bioethics 128 
and Human Biological Samples. The final study protocol was approved by an 129 
independent Ethics Committee or institutional review board at each of the 130 
participating study sites. 131 
Patients 132 
Male and female patients aged 18௅90 years with cUTI or cIAI caused by ceftazidime-133 
resistant Gram-negative pathogens were eligible for inclusion in the trial. Specified 134 
diagnoses for cUTI patients were either confirmed acute pyelonephritis or 135 
complicated lower UTI without pyelonephritis with pre-defined signs and symptoms 136 
(appendix). Patients with cIAI had to have a ceftazidime-resistant Gram-negative 137 
pathogen isolated from an abdominal source during a surgical intervention, at least 138 
one of eight specified diagnoses during surgical intervention, and specified signs or 139 
symptoms of cIAI (appendix). 140 
Patients with ongoing symptoms of either cUTI/pyelonephritis or cIAI at the 141 
time of screening and an isolated causative Gram-negative ceftazidime-resistant 142 
pathogen could be included regardless of prior antibiotic therapy. Patients who had 143 
received prior antibacterial agents that were effective in vitro against the isolated 144 
pathogen (based on the known susceptibility profile of the organism) were required 145 
to have worsening of objective symptoms or signs of infection after 48 h of therapy, 146 
or lack of improvement after 72 h of therapy. 147 
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Key exclusion criteria for both cUTI and cIAI patients included estimated 148 
creatinine clearance (CrCL) <6 mL/min by Cockcroft-Gault formula; evidence of 149 
abnormal liver function (including bilirubin, alanine aminotransferase, aspartate 150 
aminotransferase, or alkaline phosphatase levels >3× the upper limit of normal); 151 
infection due to a Gram-negative bacterial species that was unlikely to respond to 152 
ceftazidime-avibactam treatment (eg, Acinetobacter spp. and Stenotrophomonas 153 
spp.); and infection considered unlikely to respond to 5±21 days of study treatment. 154 
Patients with cIAI were also excluded from the trial if they had Acute Physiology and 155 
Chronic Health Evaluation (APACHE) II score >30; prior liver, pancreas, or small-156 
bowel transplant. Detailed exclusion criteria are summarised in the appendix. 157 
For patients to be entered into the study, ceftazidime-resistant isolates were 158 
defined as Enterobacteriaceae and P. aeruginosa with susceptibility results that were 159 
intermediate or resistant using Clinical and Laboratory Standards Institute (CLSI) 160 
criteria,14 or resistant using European Committee on Antimicrobial Susceptibility 161 
Testing (EUCAST) criteria15 when tested at the local microbiology laboratory. 162 
Specifically, for Enterobacteriaceae and P. aeruginosa, ceftazidime resistance was 163 
defined as a ceftazidime minimum inhibitory concentration (MIC) 8 mg/L and 164 
16 mg/L, respectively. The causative Gram-negative ceftazidime-resistant pathogen 165 
had to be from an abdominal source obtained during a surgical intervention in cIAI 166 
patients, and from a positive urine culture at 105 colony-forming units (CFU)/mL in 167 
cUTI patients, within 5 days prior to screening. All isolates were sent to a central 168 
laboratory for culture, identification, and susceptibility testing using CLSI criteria, and 169 
the results were used for all analyses except where unavailable, in which case local 170 
laboratory results were used. For cUTI patients, a supplementary urine culture was 171 
also taken prior to the first dose of study therapy. 172 
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All patients, or their legally acceptable representatives, were required to 173 
provide written informed consent prior to any study-specific procedures.  174 
Study endpoints 175 
The primary endpoint was assessment of clinical response (cure, failure, or 176 
indeterminate) at test-of-cure (TOC) visit 7±10 days after last infusion of study 177 
therapy in the microbiologically modified intent-to-treat population (mMITT). 178 
Definitions of clinical cure, treatment failure, and indeterminate response are 179 
summarised in the appendix. Briefly, clinical cure was defined as complete resolution 180 
or significant improvement of signs and symptoms of the index infection, such that 181 
no further antibacterial therapy (other than those allowed per protocol) was 182 
necessary. In addition, for cIAI patients, cure also required that no drainage or 183 
surgical intervention was needed after 96 h from randomisation.  184 
The mMITT population included all patients who had a diagnosis of cUTI or 185 
cIAI with at least one ceftazidime-resistant Gram-negative pathogen, as confirmed 186 
by the central laboratory, and who received at least one dose of study drug.  187 
Key secondary endpoints in the mMITT population included clinical response 188 
at other time points (end of treatment [EOT], FU1 and FU2 [cUTI only]); clinical 189 
response at TOC by (i) baseline Gram-negative pathogen isolated, and (ii) entry 190 
diagnosis; and per-patient favourable microbiological response rate at EOT, TOC, 191 
FU1, and FU2 (cUTI only) and per-pathogen favourable microbiological response 192 
rate at TOC. Other secondary outcomes not reported here due to space limitations 193 
are listed in the appendix.in the mMITT population were clinical cure at TOC by 194 
previously failed antibiotic treatment class, per-patient favourable microbiological 195 
response rate at the other visits (EOT, FU1 and FU2), favourable per-pathogen 196 
11 
microbiological response at the other visits (EOT, FU1 and FU2), favourable per-197 
pathogen microbiological response by ceftazidime-avibactam MIC, clinical and 198 
microbiological response by resistance mechanism, reasons for treatment change 199 
and/or discontinuation, and 28-day all-cause mortality rate. All outcomes as listed for 200 
the mMITT population were also evaluated for the extended microbiologically 201 
evaluable population, as well as clinical cure by previously failed antibiotic treatment 202 
class at the EOT, TOC, FU1 and FU2 visits. Finally, pharmacokinetic evaluation was 203 
performed for the individual components of ceftazidime-avibactam. 204 
Favourable microbiological response was defined as eradication or presumed 205 
eradication. Eradication was defined as absence (or urine quantification <104 206 
CFU/mL for cUTI patients) of the causative pathogen from the site of infection. In 207 
addition, if the patient was bacteraemic at screening, the bacteraemia had also 208 
resolved. As is usual for this type of cIAI study, presumed eradication was 209 
specifically used for cIAI patients where repeat cultures were not performed/clinically 210 
indicated and therefore microbiological response was presumed from clinical 211 
response. 212 
Safety and tolerability were assessed by monitoring adverse events (AEs), 213 
serious adverse events (SAEs) and laboratory parameters, including liver function 214 
tests. Patients underwent 12-lead electrocardiogram (ECG) at days 1 and 3 of study 215 
treatment (and as clinically indicated) and at the EOT visit, and vital signs checks 216 
and physical examinations were performed at each study visit. 217 
Statistical analysis 218 
Two-sided 95% confidence intervals (CI) for the treatment group response rates 219 
were calculated using the Jeffreys method.17,18 Due to the unfeasibility of recruiting 220 
12 
large numbers of patients infected with resistant Gram-negative pathogens, no 221 
formal power calculations were performed for this study, nor any formal statistical 222 
comparisons between the treatment groups. Rather, the corresponding CIs for the 223 
efficacy of best available therapy were used to provide a context for descriptive 224 
estimates of ceftazidime-avibactam efficacy.  225 
It was planned to recruit approximately 200 patients per treatment group, 226 
which was expected to provide sufficient data such that the 95% CI would extend at 227 
most ~7% on either side of the observed proportion in the overall summary, or at 228 
most 17% on either side for each separate pathogen infecting at least 30 patients, or 229 
at most 13% on either side for pathogens infecting at least 60 patients. 230 
Role of the funding source 231 
The funder of the study was responsible for study design and data collection. 232 
Together with YC, the authors employed (JA, PN, GS, AW, and LBG) or contracted 233 
(PJL) by the funder were responsible for data interpretation and writing of this report. 234 
JA, PJL, PN, GS, AW, and LBG had full access to all the data in the study, and these 235 
were discussed with YC. All authors had final responsibility for the decision to submit 236 
for publication. 237 
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5HVXOWV 238 
Patients 239 
Between January 2013 and August 2014, 333 patients were enrolled and 240 
randomised at 53 centres in 16 countries worldwide: ceftazidime-avibactam n=165 241 
(153 with cUTI and 12 with cIAI); best available therapy n=168 patients (153 with 242 
cUTI and 15 with cIAI). Although 400 patients were planned for inclusion, recruitment 243 
was ended early as it was considered that a sufficient number of patients with a 244 
suitable range of pathogens had been recruited. The proportions of randomised 245 
patients by region were: Eastern Europe 80·5%, North America and Western Europe 246 
4·8%, and rest of world 14·7%. A table of randomised patients by country and a full 247 
list of study sites and principal investigators are shown in the appendix. 248 
Most (97%) patients in the best available therapy group received a 249 
carbapenem antibiotic and the majority received this as monotherapy, with imipenem 250 
and meropenem being the most frequently prescribed agents in cUTI (50% and 37%, 251 
respectively) and cIAI patients (33% and 60%). A summary of best available therapy 252 
agents administered, and dosing information for imipenem and meropenem, are 253 
provided in the appendix. Doses of drugs used in best available therapy were 254 
generally in accordance with those recommended in product labelling. One patient 255 
randomised to ceftazidime-avibactam did not receive treatment. Therefore, 332 256 
(99·7%) patients were included in the safety population. A total of 302 (90·7%) 257 
patients were eligible for inclusion in the mMITT population (ceftazidime-avibactam, 258 
n=154; best available therapy, n=148) (figure 1). The main reason for exclusion from 259 
the mMITT population was that the ceftazidime resistance of the baseline Gram-260 
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negative study-qualifying isolate, as evaluated at the local microbiology laboratory, 261 
was not confirmed by the central laboratory. 262 
For cUTI patients, the urine culture taken at screening (documenting the 263 
presence of at least one ceftazidime-resistant Gram-negative pathogen) made the 264 
patient eligible for the trial, and for the mMITT analysis set, providing the other 265 
criteria were met (see study endpoints). The majority of cUTI patients in the mMITT 266 
analysis set had at least one ceftazidime-resistant Gram-negative pathogen in the 267 
screening urine culture that was also confirmed in the supplementary baseline urine 268 
culture, and the numbers were balanced across the treatment groups (119 patients 269 
(82.6%) in the ceftazidime-avibactam group and 112 patients (81.2%) in the best 270 
available therapy group). 271 
Baseline patient and disease characteristics, and baseline pathogen 272 
distribution, were generally similar between the treatment groups, This was true both 273 
in cUTI and cIAI, although patient numbers in the latter group were small (table 3). 274 
The majority of patients were infected with Enterobacteriaceae, most commonly K. 275 
pneumoniae and Escherichia coli (table 1). Ten cUTI patients also had bacteraemia, 276 
in nine of whom the isolates were E. coli or K. pneumoniae (the same pathogens as 277 
were isolated in their urine). None of the cIAI patients had bacteraemia. 278 
Of the 55 cUTI patient with a catheter at baseline, 24 patients (43.6%) had a 279 
catheter in place for the duration of study therapy or the catheter was only removed 280 
1 to 2 days prior to the end of study therapy (table 1). cUTI patients without 281 
pyelonephritis were required to have at least one complicating factor present at 282 
baseline. For the 127 patients with acute pyelonephritis, 17 of the 57 patients on 283 
ceftazidime-avibactam (29.8%) and 19 of the 70 patients on best available therapy 284 
15 
(27.1%) had at least one complicating factor at baseline.  The most common 285 
complicating factors present in these 36 patients were partial obstructive uropathy 286 
(19 patients) and urogenital procedure within 7 days prior to study entry (13 287 
patients). 288 
Figure 2 shows ceftazidime and ceftazidime-avibactam MICs for baseline 289 
Gram-negative pathogens isolated from urine in cUTI patients, including study-290 
qualifying ceftazidime-resistant pathogens, and any other (ceftazidime-susceptible) 291 
pathogens isolated. As determined by the central microbiology laboratory, 99·2% of 292 
all Enterobacteriaceae isolated from urine in the ceftazidime-avibactam group and 293 
95·7% of those in the best available therapy group were ceftazidime-resistant (MIC 294 
8 mg/L). In contrast, only 1·5% of Enterobacteriaceae were shown as non-295 
susceptible to ceftazidime-avibactam (MIC 8 mg/L was considered provisionally 296 
susceptible and MIC >8 mg/L as provisionally resistant to ceftazidime-avibactam). In 297 
each treatment group, the ceftazidime-avibactam MIC50 and MIC90 were 0·25 and 1 298 
mg/L, respectively, for E. coli, and 0·5 and 1 mg/L for K. pneumoniae. With the 299 
exception of one isolate, all P. aeruginosa isolated from the urine of cUTI patients 300 
were resistant to ceftazidime (MIC >16 mg/L). In the mMITT analysis set, nine of the 301 
14 baseline P. aeruginosa isolates in the ceftazidime-avibactam group for cUTI 302 
patients had a ceftazidime-avibactam MIC >8 mg/L ± that is, were provisionally 303 
resistant. 304 
Four cUTI patients in the ceftazidime-avibactam group had Gram-negative 305 
bacteraemia at baseline, with all blood isolates identified as K. pneumoniae or E coli. 306 
All the K. pneumoniae blood isolates and four of five E. coli were resistant to 307 
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ceftazidime, but all were within the provisional range of susceptibility for ceftazidime-308 
avibactam (MIC 8 mg/L). 309 
In all except seven cUTI patients in the best available therapy group, MIC 310 
values to the relevant best available therapy were in the susceptible range according 311 
to the central laboratory for all baseline pathogens isolated from urine. In all six cUTI 312 
patients in the best available therapy group who had Gram-negative bacteraemia at 313 
baseline (K. pneumoniae or E. coli), MICs were in the susceptible range to the best 314 
available therapy received. For one E. coli blood isolate in the best available therapy 315 
group, the ceftazidime MIC was 4 mg/L.  316 
In the cIAI population, 95.5% of Enterobacteriaceae isolated from the intra-317 
abdominal site were resistant to ceftazidime (MIC 8 mg/L), and 100% had 318 
ceftazidime-avibactam MICs within the provisional range of susceptibility. Only one 319 
cIAI patient in the ceftazidime-avibactam group had a P. aeruginosa isolate and this 320 
was provisionally resistant to ceftazidime-avibactam (MIC >8 mg/L).  321 
Clinical cure rates 322 
The overall clinical cure rate at TOC in the mMITT population (cUTI and cIAI 323 
combined) was similar with ceftazidime-avibactam (140/154 [90·9%; 95% CI, 85·6, 324 
94·7]) and best available therapy (135/148 [91·2%; 95% CI, 85·9, 95·0]).  325 
cUTI patients 326 
In the cUTI group, clinical cure rates at TOC were similar between treatment groups 327 
(ceftazidime-avibactam: 132/144 [91·7%; 95% CI, 86·3, 95·4] and best available 328 
therapy: 129/137 [94·2%; 95% CI 89·3, 97·2]) (figure 3A). Among those with acute 329 
pyelonephritis, clinical cure rates at TOC were 91·2% (52/57) with ceftazidime-330 
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avibactam and 90·0% (63/70) with best available therapy. Among those without 331 
acute pyelonephritis, clinical cure rates at TOC were 92·0% (80/87) and 98·5% 332 
(66/67), respectively. In terms of later time points, clinical cure rates decreased 333 
slightly over time in both treatment groups, but remained 85% with ceftazidime-334 
avibactam, generally achieving similar clinical cure rates to best available therapy at 335 
each visit (appendix, figure S2A). 336 
Clinical cure rates at TOC by baseline Gram-negative pathogen isolated from 337 
urine were generally high and similar in both treatment groups (figure 4A). 338 
cIAI patients 339 
The proportion of cIAI patients with clinical cure at TOC was 80·0% (8/10; 95% CI 340 
47·9, 95·6) in the ceftazidime-avibactam plus metronidazole group, and 54·5% (6/11; 341 
95% CI 27·0, 80·0) in the best available therapy group (figure 3A). The CIs were 342 
very wide due to the small number of cIAI patients. Clinical cure rates remained the 343 
same at FU1 (last follow-up in cIAI patients) in both treatment groups (appendix). 344 
Per-patient microbiological response rates 345 
cUTI patients 346 
Per-patient favourable microbiological response rates at TOC in the cUTI population 347 
were higher with ceftazidime-avibactam (118/144 [81·9%; 95% CI, 75·1, 87·6]) than 348 
with best available therapy (88/137 [64·2%; 95% CI, 56·0, 71·9]) (figure 3B). Among 349 
patients with acute pyelonephritis, per-patient favourable microbiological response 350 
rates at TOC were 87·7% (50/57) with ceftazidime-avibactam and 70·0% (49/70) 351 
with best available therapy; corresponding rates in patients without pyelonephritis 352 
were 78·2% (68/87) and 58·2% (39/67), respectively. In the mMITT analysis set, the 353 
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per-patient favourable microbiological response rate at TOC in patients receiving 354 
best available therapy with acute pyelonephritis was similar whether at least 1 355 
complicating factor was present at baseline or not (68.4% and 70.6%, respectively). 356 
For patients with acute pyelonephritis in the ceftazidime-avibactam arm, the 357 
favourable microbiological response rate at TOC was 94.1% and 85.0%, 358 
respectively. However, the number of acute pyelonephritis patients with at least 1 359 
complicating factor was small. 360 
Consistent with the natural history of cUTI, the per-patient microbiological 361 
response was slightly lower at subsequent visits after TOC (appendix, figure S2B). 362 
However, at each subsequent visit, the response rates were consistently higher for 363 
ceftazidime-avibactam than for best available therapy.  364 
Favourable microbiological response rates for E. coli and K. pneumoniae 365 
isolated from urine in cUTI patients were higher in the ceftazidime-avibactam group 366 
than in the best available therapy group (88·1% vs 66·7%, respectively for E. coli, 367 
and 83·6% vs 66·2% for K. pneumoniae [figure 4B]). 368 
Favourable microbiological responses to ceftazidime-avibactam at TOC in 369 
cUTI patients were demonstrated at ceftazidime-avibactam MICs of 8 mg/L for all 370 
Enterobacteriaceae and P. aeruginosa isolates (i.e. just within the provisional range 371 
of susceptibility).. Seven of nine cUTI patients in the ceftazidime-avibactam group 372 
with provisionally resistant P. aeruginosa isolates (ceftazidime-avibactam MIC >8 373 
mg/L) had a favourable microbiological response at TOC. Two of the 132 baseline 374 
Enterobacteriaceae isolates from cUTI patients were provisionally resistant to 375 
ceftazidime-avibactam (MIC >8 mg/L), and both patients had an unfavourable 376 
microbiological response at TOC. 377 
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Given the small number of patients in the study, no other sub-group analyses 378 
for the per-patient microbiological response in cUTI patients were planned. However, 379 
catheter use at baseline, and by best available therapy received, were investigated 380 
post-hoc. Per-patient favourable microbiological response rates at TOC were similar 381 
in the ceftazidime-avibactam group whether a catheter was present at baseline or 382 
not (25 out of 30 patients (83.3%) and 93 out of 114 patients (81.6%), respectively). 383 
For patients receiving best available therapy, the favourable microbiological 384 
response rate at TOC was lower in those patients with a catheter at baseline (13 out 385 
of 25 patients (52.0%)) compared to those without a catheter at baseline (75 out of 386 
112 patients (67.0%)). However, the number of patients with a catheter at baseline 387 
was small (30 patients on ceftazidime-avibactam and 25 patients on best available 388 
therapy).  389 
With regards to best available therapy, imipenem or meropenem monotherapy 390 
were the most common antibiotics used for cUTI patients (72 patients and 46 391 
patients respectively (in the mMITT analysis set)). Other best available therapy 392 
options (monotherapy or combination therapy) were used in the remaining 19 393 
patients. In the mMITT analysis set, the favourable per-patient microbiological 394 
response at TOC for cUTI patients was lower for patients receiving imipenem 395 
monotherapy (39 out of 72 patients (54.2%) compared to meropenem monotherapy 396 
(37 out of 46 patients (80.4%)) or other best available therapy (12 out of 19 patients 397 
(63.2%)). 398 
 399 
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cIAI patients 400 
For cIAI patients, per-patient microbiological outcomes at TOC, and per-pathogen 401 
favourable microbiological response among Gram-negative pathogens isolated from 402 
the intra-abdominal site, were presumed from the clinical response (figure 3B and 403 
figure 4C, respectively). One cIAI patient in the ceftazidime-avibactam plus 404 
metronidazole group had a P. aeruginosa isolate with a ceftazidime-avibactam MIC 405 
>8 mg/L at baseline. This patient had a favourable microbiological response at TOC. 406 
Other secondary outcomes 407 
The results for all other secondary outcomes are summarised in the appendix. 408 
Safety 409 
The median (range) duration of treatment with ceftazidime-avibactam and best 410 
available therapy was 10 (2 to 21) and 10 (2 to 21) days, respectively, in cUTI, and 411 
10·5 (6 to 21) and 12 (4 to 23) days in cIAI. By the last follow-up visit (28௅35 days 412 
post-randomisation), 51/164 patients (31·1%) in the ceftazidime-avibactam group 413 
and 66/168 (39·3%) in the best available therapy group had experienced AEs, the 414 
majority of which were mild or moderate in intensity. Gastrointestinal disorders were 415 
the most frequently reported treatment-emergent AEs with both ceftazidime-416 
avibactam (21/164 patients, 12·8%) and best available therapy (30/168 417 
patients,17·9%) (table 2). 418 
Three AEs leading to discontinuation of study drug occurred: one patient 419 
(0·6%) in the ceftazidime-avibactam group and two (1·2%) in the best available 420 
therapy group. Seven patients experienced an AE with an outcome of death, none of 421 
which were considered related to study drug by the investigator. In the ceftazidime-422 
avibactam group, the AEs with an outcome of death (occurring in one cUTI patient 423 
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each) were: cardiorespiratory arrest, cardiac arrest and renal failure. For patients on 424 
best available therapy, the events with an outcome of death were cardiac arrest (two 425 
cUTI patients), acute respiratory failure (one cUTI patient) and lobar pneumonia (one 426 
cIAI patient). 427 
The incidence of AEs considered related to study drug by the investigator was 428 
low (ceftazidime-avibactam 14/164 patients, 8·5%, best available therapy 11/168 429 
patients, 6·5%). Overall, nine patients in the ceftazidime-avibactam group and ten 430 
patients in the best available therapy group experienced SAEs, but none were 431 
considered related to study drug. There were no new safety concerns identified for 432 
ceftazidime-avibactam, including for any of the clinical laboratory, ECG, physical 433 
examination, or vital signs assessments. 434 
 435 
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'LVFXVVLRQ 436 
Serious infections due to resistant Gram-negative pathogens are difficult to treat and 437 
have few treatment options. Thus, patients with these infections have adverse 438 
outcomes. Most clinical trials are limited in their ability to provide evidence of efficacy 439 
against infections caused by resistant organisms, since their design does not favour 440 
the inclusion of large number of patients with such organisms. The REPRISE study 441 
is the first pathogen-directed clinical trial for ceftazidime-avibactam examining its 442 
effectiveness against ceftazidime-resistant Gram-negative pathogens. Therefore, 443 
this study provides valuable information for clinicians and represents an important 444 
addition to the ceftazidime-avibactam trial programme, providing supporting data for 445 
the pivotal phase 3 trials in cIAI and cUTI.  446 
The REPRISE study met its primary endpoint, demonstrating a similar overall 447 
clinical cure rate at TOC with ceftazidime-avibactam and best available therapy in 448 
the mMITT population (90·9% vs 91·2%, respectively). The majority of ceftazidime-449 
resistant pathogens were in the provisionally susceptible MIC range for ceftazidime-450 
avibactam, and further analysis is ongoing to evaluate those that were not. Molecular 451 
characterisation of the isolates from the study is also ongoing. Seven of nine cUTI 452 
patients in the ceftazidime-avibactam group with provisionally resistant P. 453 
aeruginosa isolates (ceftazidime-avibactam MIC >8 mg/L) had a favourable 454 
microbiological response at TOC. This observation of an apparent response to an 455 
agent to which pathogens are non-susceptible is well known and not unique to this 456 
study.  A review of antibacterial clinical trials spanning 30 years characterized the 457 
³-UXOH´ZKHUHE\LQIHFWLRQVGXHWRVXVFHSWLEOHLVRODWHVUHVSRQGWRWKHUDS\458 ׽90% of the time, whereas infections due to resistant isolates respond ׽60% of the 459 
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time.19 In addition, ceftazidime-avibactam is excreted in the urine to high levels, 460 
potentially contributing to a favourable microbiological response in these patients 461 
with a provisionally resistant isolate. A higher microbiological response rate was 462 
observed for ceftazidime-avibactam compared with best available therapy in cUTI 463 
patients, the reason for which not clear. Imipenem was the most common antibiotic 464 
used as best available therapy for cUTI patients, and there were more with an 465 
unfavourable microbiological response at TOC in those who received imipenem 466 
compared with other best available therapy. Although dosing of imipenem was in line 467 
with labelling, a variety of doses were used and some patients received doses at the 468 
lower end of the recommended range. However, given that the baseline MICs of 469 
study treatment received were low, and generally well within the susceptible range 470 
for the antibiotic administered, it is difficult to draw any conclusions from this 471 
observation. No new safety signals for ceftazidime-avibactam were identified, and 472 
the overall safety profile was similar to that reported previously for ceftazidime 473 
alone20 and the cephalosporin class. 474 
The main limitation to the REPRISE study was the open-label nature of the 475 
trial. Open label administration was mandated in order to allow choice of best 476 
available therapy against resistant organisms with variable susceptibility patterns. 477 
This limitation was offset partly by the requirement for the individual investigators to 478 
define their choice of best available therapy prior to randomisation. Furthermore, the 479 
study found high rates of microbiological response compared with best available 480 
therapy, which is an objective assessment and therefore unlikely to have been 481 
affected by the study design. Another potential limitation was the predominance of 482 
patient recruitment from Eastern Europe compared with the other regions, but 483 
recruitment was generally well balanced between the treatment groups with regard 484 
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to geographic distribution. The small number of cIAI patients enrolled meant that the 485 
study results only allowed for general descriptions of treatment-related trends for this 486 
population. However, the RECLAIM 1 and 2 studies in cIAI (reported as a single 487 
study database) included 529 patients treated with ceftazidime-avibactam plus 488 
metronidazole, which was shown to be non-inferior to meropenem.10 Results in the 489 
subset of patients with infections due to ceftazidime-resistant Gram-negative 490 
pathogens were consistent with the primary results of this study.  491 
In conclusion, treatment of serious ceftazidime-resistant Gram-negative cUTI 492 
with ceftazidime-avibactam results in similar clinical cure rates to treatment with best 493 
available therapy and numerically higher per-patient favourable microbiological 494 
response rates. In cIAI, clinical and microbiological response rates were also high for 495 
ceftazidime-avibactam and in line with those observed with best available therapy. 496 
However, the number of cIAI patients in this study was small, limiting the 497 
interpretation of the findings in this population. The safety and tolerability profile of 498 
ceftazidime-avibactam reported here is broadly similar to the recognised profile of 499 
ceftazidime alone. These promising results support the use of ceftazidime-avibactam 500 
as a potential alternative to carbapenems in patients with resistant Gram-negative 501 
infections. 502 
  503 
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5HVHDUFKLQFRQWH[W 504 
Evidence before this study 505 
PubMed search terms: [ceftazidime-avibactam AND randomised] 506 
ECCMID 2015 search term: [ceftazidime-avibactam] 507 
PubMed searches using the above terms identified three reports of phase 1 trials 508 
assessing the safety, tolerability and pharmacokinetics of ceftazidime-avibactam,21±23 509 
and two phase 2 trials of ceftazidime-avibactam in patients with cUTI and cIAI 510 
caused by Gram-negative pathogens.7,8 The phase 2 trial in cUTI patients 511 
demonstrated clinical response rates with ceftazidime-avibactam comparable to 512 
those for imipenem-cilastatin.8 In cIAI patients, ceftazidime-avibactam (in 513 
combination with metronidazole) achieved response rates comparable to those 514 
achieved with meropenem.7 Both studies included some patients with ceftazidime-515 
resistant infections, but this was not an inclusion criterion in either trial.  516 
The ECCMID 2015 search identified the results of some phase 3 studies of 517 
ceftazidime-avibactam: the REPRISE study reported in this paper,24 and a single 518 
report of two identical phase 3 studies in cIAI (RECLAIM 1 and 2), which included 519 
some patients with ceftazidime-resistant Gram-negative infections.10 Ceftazidime-520 
avibactam plus metronidazole was shown to be non-inferior to meropenem. 521 
Other ongoing or recently completed (but not yet published) phase 3 trials of 522 
ceftazidime-avibactam, including patients with cUTI, cIAI, or nosocomial pneumonia, 523 
also included all-comers rather than specifically recruiting patients with ceftazidime-524 
resistant infections. 525 
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Added value of this study 526 
The REPRISE study was specifically designed to evaluate the efficacy of 527 
ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant 528 
Gram-negative cUTI and cIAI. Clinical cure rates were similar in both treatment 529 
groups, with numerically higher per-patient favourable microbiological response rates 530 
in the ceftazidime-avibactam group. The observed safety and tolerability ceftazidime-531 
avibactam was similar to the recognised profile of ceftazidime alone. 532 
Implications of all the available evidence 533 
These promising results support the further development of ceftazidime-avibactam 534 
as a potential alternative to carbapenems in patients with resistant Gram-negative 535 
infections. 536 
  537 
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Table 1: Baseline patient characteristics and infection type (mMITT population)  
 
cUTI cIAI 
Ceftazidime-avibactam 
(n=144) 
BAT 
(n=137) 
Ceftazidime-avibactam + 
metronidazole (n=10) 
BAT 
(n=11) 
Age, years; mean (SD) 64·3 (14·6) 61·3 (15·3) 49·9 (16·1) 68·4 (11·1) 
 75±90 years, n (%) 38 (26·4) 27 (19·7) 0 4 (36·4) 
Female, n (%) 64 (44·4) 63 (46·0) 6 (60·0) 4 (36·4) 
Race, n (%)     
 White 136 (94·4) 131 (95·6) 9 (90·0) 11 (100) 
 Other 8 (5·6) 6 (4·4) 1 (10·0) 0 
Body mass index, kg/m2; mean (SD) 28·1 (5·5) 28·0 (5·8) 25·2 (6·3) 28·6 (4·6) 
  30 kg/m2, n (%) 48 (33·3) 51 (37·2) 3 (30·0) 4 (36·4) 
Renal status, creatinine clearance; mL/min, n (%)     
 >50 118 (81·9) 113 (82·5) 10 (100) 6 (54·5) 
 31±50  19 (13·2) 18 (13·1) 0 3 (27·3) 
  16±30 4 (2·8) 5 (3·6) 0 2 (18·2) 
  6±15 3 (2·1) 1 (0·7) 0 0 
Diagnosis cUTI, n (%)     
 Acute pyelonephritis 57 (39·6) 70 (51·1) N/A N/A 
35 
 cUTI without pyelonephritis 87 (60·4) 67 (48·9) N/A N/A 
 Complicating factors     
  Partial obstructive uropathy 45 (31·3) 21 (15·3) N/A N/A 
  Abnormality of urogenital tract 39 (27·1) 38 (27·7) N/A N/A 
  Male with urinary retention 33 (22·9) 24 (17·5) N/A N/A 
  Catheterisation 30 (20·8) 25 (18·2) N/A N/A 
  Urogenital procedure within 7 days 27 (18·8) 21 (15·3) N/A N/A 
Diagnosis cIAI, n (%)     
 Cholecystitis N/A N/A 2 (20·0) 4 (36·4) 
 Diverticular disease N/A N/A 1 (10·0) 1 (9·1) 
Appendiceal perforation or per-appendiceal 
abscess 
N/A N/A 2 (20·0) 0 
 Secondary peritonitis N/A N/A 3 (30·0) 2 (18·2) 
  Intra-abdominal abscess (1) N/A N/A 2 (20·0) 4 (36·4) 
  APACHE II score, mean (SD)Á N/A N/A 6·9 (5·8) 10·9 (4·4) 
  APACHE II score category N/A N/A   
    N/A N/A 8 (80·0) 6 (54·5) 
   >10± N/A N/A 1 (10·0) 3 (27·3) 
Prior antibiotic use, n (%) 72 (50·0) 63 (46·0) 10 (100) 11 (100) 
36 
Bacteraemia, yes; n (%)¶ 4 (2·8) 6 (4·4) 0 0 
Infection type, n (%)     
 Monomicrobial 139 (96·5) 131 (95·6) 4 (40·0) 4 (36·4) 
 Polymicrobial (2 pathogens) 4 (2·8) 6 (4·4) 4 (40·0) 5 (45·5) 
 Polymicrobial (3 pathogens) § 1 (0·7) 0 2 (20·0) 2 (18·2) 
Baseline pathogen in urine (cUTI) or intra-abdominal  
site (cIAI), n (%)Œ 
 Enterobacteriaceae 131 (91·0) 132 (96·4) 9 (90·0) 11 (100) 
  Escherichia coli 59 (41·0) 57 (41·6) 4 (40·0) 6 (54·5) 
  Klebsiella pneumoniae 55 (38·2) 65 (47·4) 5 (50·0) 3 (27·3) 
  Enterobacter cloacae 8 (5·6) 6 (4·4) 3 (30·0) 1 (9·1) 
 Pseudomonas aeruginosa 14 (9·7) 5 (3·6) 1 (10·0) 1 (9·1) 
Black or African American, Asian, or other. 
ÁData available for nine patients in each group. 
¶Pathogens identified in blood were Klebsiella pneumoniae (4), Escherichia coli (5), Bacteroides fragilis (1), and Clostridium ramosum (1). 
§Maximum of two uropathogens permitted for study entry; however, one cUTI patient in the ceftazidime-avibactam group had one Gram-negative pathogen 
(Proteus mirabilis) in the urine and two anaerobes in the blood. 
ŒOther pathogens identified in urine were: Citrobacter freundii complex (5 patients), Proteus mirabilis (6 patients), Serratia marcescens (2 patients), and (in 
1 patient each) Enterobacter aerogenes, Klebsiella oxytoca, Klebsiella ozaenae, Morganella morganii, Proteus rettgeri, Providencia stuartii, Raoultella 
terrigena, and Ochrobactrum anthropi. Other pathogens identified in intra-abdominal site were: Citrobacter freundii complex (2 patients), Gram-positive 
aerobes (7 patients), and anaerobes (4 patients).  
37 
APACHE=Acute Physiology and Chronic Health Evaluation; BAT=best available therapy; cIAI=complicated intra-abdominal infection; cUTI=complicated 
urinary tract infection; mMITT=microbiologically modified intent-to-treat; SD=standard deviation. 
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Table 2: Adverse events* (safety population)  
 cUTI cIAI 
Preferred term, n (%) 
Ceftazidime-
avibactam 
(n=152) 
BAT 
(n=153) 
Ceftazidime-
avibactam + 
metronidazole 
(n=12) 
BAT 
(n=15) 
Patients with any AE 43 (28·3) 54 (35·3) 
8 (66·7) 12 
(80·0) 
Nausea 5 (3·3) 9 (5·9) 3 (25·0) 1 (6·7) 
Vomiting 4 (2·6) 2 (1·3) 2 (16·7) 1 (6·7) 
Diarrhoea 3 (2·0) 8 (5·2) 2 (16·7) 0 
Pyrexia 4 (2·6) 2 (1·3) 0 0 
Abdominal pain 3 (2·0) 4 (2·6) 0 1 (6·7) 
Dyspepsia 2 (1·3) 5 (3·3) 0 0 
Headache 1 (0·7) 11 (7·2) 2 (16·7) 1 (6·7) 
Oedema peripheral 3 (2·0) 1 (0·7) 0 0 
Vulvovaginal 
candidiasis 3 (2·0) 0 
0 0 
Insomnia 2 (1·3) 0 2 (16·7) 4 (26·7) 
Nasal congestion 1 (0·7) 0 2 (16·7) 0 
Phlebitis 1 (0·7) 2 (1·3) 2 (16·7) 1 (6·7) 
Back pain 0 0 2 (16·7) 0 
Paraesthesia 0 0 2 (16·7) 0 
Respiratory failure 0 0 0 2 (13·3) 
$(VRFFXUULQJLQSDWLHQWVIRUF87,DQGRUSDWLHQWVIRUF,$, (ceftazidime-avibactam or BAT), 
and with onset time on or after time of first dose and up to and including last follow-up visit (FU2 for 
cUTI, FU1 for cIAI), irrespective of relationship to study drug. 
AE=adverse events; BAT=best available therapy; cIAI=complicated intra-abdominal infection; 
cUTI=complicated urinary tract infection; FU1=follow-up 1; FU2=follow-up 2. 
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Figure 1: Study flow 
 
AE=adverse event; BAT=best available therapy; cIAI=complicated intra-abdominal infection; 
cUTI=complicated urinary tract infection; mMITT=microbiologically modified intent-to-treat; TOC=test 
of cure visit. 
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Figure 2: Ceftazidime and ceftazidime-avibactam MIC for all 
Enterobacteriaceae isolated from urine at baseline in cUTI patients (mMITT 
population)  
 
 
*Number of pathogens. Some patients had more than one baseline Gram-negative pathogen and one 
of those may have been ceftazidime-susceptible. 
BAT=best available therapy; CAZ-AVI=ceftazidime-avibactam; cUTI=complicated urinary tract 
infection; MIC=minimum inhibitory concentration; mMITT=microbiologically modified intent-to-treat. 
 
 
42 
Figure 3: (A) Clinical response rate (95% CI) at TOC (mMITT population); 
(B) per-patient favourable microbiological response rate (95% CI) at TOC 
(mMITT population)* 
 
 
*Per-patient microbiological outcomes for cIAI patients were presumed from clinical response. 
BAT=best available therapy; CAZ-AVI=ceftazidime-avibactam; CI=confidence interval; 
cIAI=complicated intra-abdominal infection; cUTI=complicated urinary tract infection; 
mMITT=microbiologically modified intent-to-treat; TOC=test of cure visit. 
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Figure 4: Per-pathogen response rates at TOC among Gram-negative 
pathogens isolated at baseline: (A) clinical response rates per pathogen 
isolated from urine in cUTI patients; (B) favourable microbiological response 
rates per pathogen isolated from urine in cUTI patients; (C) favourable 
microbiological response rates per pathogen isolated from intra-abdominal 
site in cIAI patients (mMITT population)* 
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*Some patients had more than one baseline Gram-negative pathogen. 
BAT=best available therapy; CAZ-AVI=ceftazidime-avibactam; cIAI=complicated intra-abdominal 
infection; cUTI=complicated urinary tract infection; mMITT=microbiologically modified intent-to-treat; 
NC=not calculated; TOC=test of cure visit. 
 
 
